Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
AssigneeKaloBios Pharmaceuticals, Inc.
InventorsChristopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
Claims27
A method of killing myeloproliferative disorder cells that express EphA3 on the cell surface, the method comprising contacting the cells with an anti-EphA3 antibody, wherein the anti-EphA3 antibody (i) activates EphA3 and (ii) induces antibody-dependent cell-mediated cytotoxicity (ADCC), wherein the myeloproliferative disorder cells are chronic myeloid proliferative disorder cells;
- or myeloid leukemia cells.
A method of treating a patient that has a chronic myeloproliferative disorder or a myeloid leukemia and has myeloproliferative disorder cells that express EphA3 on the cell surface, the method comprising administering a therapeutically effective amount of an anti-EphA3 antibody to the patient, wherein the anti-EphA3 antibody (i) activates EphA3 and (ii) induces antibody-dependent cell-mediated cytotoxicity (ADCC).
A method of monitoring the efficacy of treatment of a patient having a myeloproliferative disorder with EphA3+ myeloproliferative cells, wherein the myeloproliferative disorder is AML or MDS, the method comprising:
- obtaining a sample comprising myeloproliferative disorder stem cells and/or blast cells from the patient following a therapeutic treatment for the myeloproliferative disorder;
- and
- detecting expression of EphA3 on the myeloproliferative disorder stem cells and/or blast cells.
Dependencies are inferred from the claim text.